215 related articles for article (PubMed ID: 22437966)
1. Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.
Murphy AJ; Axt JR; de Caestecker C; Pierce J; Correa H; Seeley EH; Caprioli RM; Newton MW; de Caestecker MP; Lovvorn HN
Int J Cancer; 2012 Sep; 131(6):E983-94. PubMed ID: 22437966
[TBL] [Abstract][Full Text] [Related]
2. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract][Full Text] [Related]
3. Genetic and chromosomal alterations in Kenyan Wilms Tumor.
Lovvorn HN; Pierce J; Libes J; Li B; Wei Q; Correa H; Gouffon J; Clark PE; Axt JR; Hansen E; Newton M; O'Neill JA;
Genes Chromosomes Cancer; 2015 Nov; 54(11):702-15. PubMed ID: 26274016
[TBL] [Abstract][Full Text] [Related]
4. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
5. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
6. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor.
Murphy AJ; Pierce J; de Caestecker C; Taylor C; Anderson JR; Perantoni AO; de Caestecker MP; Lovvorn HN
J Pediatr Surg; 2012 Jun; 47(6):1239-49. PubMed ID: 22703800
[TBL] [Abstract][Full Text] [Related]
7. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
9. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
10. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
13. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
Brown KW; Charles A; Dallosso A; White G; Charlet J; Standen GR; Malik K
Cancer Genet; 2012 Jun; 205(6):319-26. PubMed ID: 22749038
[TBL] [Abstract][Full Text] [Related]
14. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
Maiti S; Alam R; Amos CI; Huff V
Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
[TBL] [Abstract][Full Text] [Related]
15. β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.
Clark PE; Polosukhina D; Love H; Correa H; Coffin C; Perlman EJ; de Caestecker M; Moses HL; Zent R
Am J Pathol; 2011 Dec; 179(6):3045-55. PubMed ID: 21983638
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
18. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
19. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
20. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
